Nextleaf Solutions Ltd.

Nextleaf Solutions Ltd. operates as a cannabis extraction technology enterprise, pioneering and licensing advanced methods for the processing, refinement, and development of cannabinoid formulations throughout Canada. The company is actively involved in the extraction, distillation, and purification of CBD oils and THC ingredients, which it subsequently distributes and sells wholesale. Its operations further encompass comprehensive research and development for cannabis-infused products, including vaporizers, edible concentrates, and specialized extracts, in addition to providing expert extraction services. Nextleaf also dedicates efforts to the creation and market introduction of psychoactive compounds. Established in 2015, the firm is headquartered in Vancouver, Canada, and was previously known as Legion Metals Corp.

Nextleaf Solutions Ltd. trades as OILS.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $11.26M of revenue and -$162,944 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Nextleaf Solutions Ltd. can be compared against peers such as Blueberries Medical Corp., Christina Lake Cannabis Corp., CLS Holdings USA, Inc., Crescita Therapeutics Inc., Delivra Health Brands Inc., Lobe Sciences Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $8.50M, beta of 0.89, and return on equity of -3.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

OILS.CN currently shows total debt of $793,817 and beta of 0.89. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.nextleafsolutions.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.